Agios Pharmaceuticals, Inc.
A biopharmaceutical company in Cambridge, Massachusetts, that develops treatments for rare blood disorders by targeting cellular metabolism. Its main product, PYRUKYND (mitapivat), is an oral medicine for hemolytic anemia in adults with pyruvate kinase deficiency. Founded in 2008 by three cancer researchers, the company takes its name from the Greek word for "holy" — and sold its cancer business in 2021 to focus on rare genetic diseases.
Granted 286.6K · Sold 273.8K
Granted 351.8K · Sold 167.2K
Granted 156.5K · Sold 45.1K
Granted 131.3K · Sold 51.0K
Granted 80.3K · Sold 27.7K
Granted 101.7K · Sold 54.1K
Granted 72.2K · Sold 25.3K
Granted 1.6K
Granted 17.9K
Granted 17.3K · Sold 2.4K
Granted 14.9K
Granted 14.0K
Granted 35.2K · Sold 20.0K
Granted 15.2K
Granted 39.9K · Sold 31.0K
Granted 10.9K
Granted 8.9K
Granted 16.2K · Sold 5.9K
Granted 11.3K
Granted 1.6K
Granted 1.6K
Granted 2.0K
Granted 31.2K · Sold 32.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Schenkein David PDirector · 30 transactions | +2.6% | 476.1Kas of Jun 2024 | 286.6K | — | 273.8K |
| Goff BrianChief Executive Officer, Director · 38 transactions | — | 191.1K | 351.8K | — | 167.2K |
| Fouse Jacqualyn ADirector · 21 transactions | +164.1% | 154.2K | 156.5K | — | 45.1K |
| Gheuens SarahChief Medical Officer · 57 transactions | — | 80.3K | 131.3K | — | 51.0K |
| Jones CeciliaChief Financial Officer · 30 transactions | — | 55.0K | 80.3K | — | 27.7K |
| Burns James WilliamChief Legal Officer · 50 transactions | — | 49.3K | 101.7K | — | 54.1K |
| Milanova TsvetaChief Commercial Officer · 22 transactions | — | 46.8K | 72.2K | — | 25.3K |
| Maraganore JohnDirector · 2 transactions | +0.3% | 28.5Kas of Sep 2022 | 1.6K | — | — |
| Biller JonathanChief Financial Officer · 6 transactions | +128.6% | 23.0Kas of Feb 2022 | 17.9K | — | — |
| Scadden DavidDirector · 17 transactions | +268.9% | 20.4K | 17.3K | — | 2.4K |
| Ho MaykinDirector · 5 transactions | +299.8% | 19.8K | 14.9K | — | — |
| Car BruceChief Scientific Officer · 6 transactions | +102.2% | 16.8Kas of Feb 2022 | 14.0K | — | — |
| Ballal Rahul D.Director · 13 transactions | — | 15.2K | 35.2K | — | 20.0K |
| Smith CynthiaDirector · 6 transactions | — | 15.2K | 15.2K | — | — |
| Foster-Cheek Kaye IDirector · 12 transactions | — | 12.5K | 39.9K | — | 31.0K |
| Capello Jeffrey DDirector · 5 transactions | — | 10.9K | 10.9K | — | — |
| Owen Adams CatherineDirector · 4 transactions | — | 10.9K | 8.9K | — | — |
| Viswanadhan KrishnanChief Corp Dev & Strategy · 4 transactions | — | 10.3K | 16.2K | — | 5.9K |
| Poddar RichaChief Commercial Officer · 9 transactions | — | 8.5Kas of Oct 2022 | 11.3K | — | — |
| Clark Ian TDirector · 1 transaction | +31.9% | 6.5Kas of May 2022 | 1.6K | — | — |
| Clancy Paul JDirector · 1 transaction | +31.9% | 6.5Kas of May 2022 | 1.6K | — | — |
| Owen Catherine E.Director · 1 transaction | — | 2.0Kas of Jun 2024 | 2.0K | — | — |
| Washburn Theodore James Jr.Principal Accounting Officer · 47 transactions | -65.5% | 868 | 31.2K | — | 32.2K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -735.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.